Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety,
efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.